Michael Morrissey - Exelixis CEO and President and Director
| EXEL Stock | USD 23.71 0.42 1.80% |
CEO
Dr. Michael M. Morrissey, Ph.D. is President, Chief Executive Officer, Director of the Company. He has served as a director and as Exelixis President and Chief Executive Officer since July 2010. Dr. Morrissey has held positions of increasing responsibility at Exelixis since he joined the company in February 2000, including serving as President of Research and Development from January 2007 until July 2010. From 1991 to 2000, Dr. Morrissey held several positions at Berlex Biosciences, last holding the position of Vice President, Discovery Research. Earlier in his career, Dr. Morrissey served as a Senior Scientist and Project Team Leader in Medicinal Chemistry at CIBAGeigy Corporationrationration. He is the author of numerous scientific publications in medicinal chemistry and drug discovery and an inventor on 70 issued U.S. patents and 25 additional published U.S. patent applications since 2010.
| Age | 63 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Address | 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502 |
| Phone | 650 837 7000 |
| Web | https://www.exelixis.com |
Michael Morrissey Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Morrissey against Exelixis stock is an integral part of due diligence when investing in Exelixis. Michael Morrissey insider activity provides valuable insight into whether Exelixis is net buyers or sellers over its current business cycle. Note, Exelixis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Exelixis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Morrissey over a month ago Disposition of 100 shares by Michael Morrissey of Selective Insurance at 79.75 subject to Rule 16b-3 | ||
Michael Morrissey over a month ago Disposition of 23304 shares by Michael Morrissey of Exelixis at 21.51 subject to Rule 16b-3 |
Exelixis Management Efficiency
The company has return on total asset (ROA) of 0.0355 % which means that it generated a profit of $0.0355 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0874 %, meaning that it created $0.0874 on every $100 dollars invested by stockholders. Exelixis' management efficiency ratios could be used to measure how well Exelixis manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Exelixis' Return On Tangible Assets are quite stable compared to the past year. Return On Capital Employed is expected to rise to 0.13 this year, although the value of Return On Equity will most likely fall to 0.10. At this time, Exelixis' Other Assets are quite stable compared to the past year. Net Tangible Assets is expected to rise to about 2.9 B this year, although the value of Intangibles To Total Assets will most likely fall to 0.02.Similar Executives
| Found 9 records | CEO Age | ||
| Amy MBA | Terns Pharmaceuticals | 53 | |
| Denise ScotsKnight | Mereo BioPharma Group | 65 | |
| Frank BeduAddo | PDS Biotechnology Corp | 59 | |
| Adi Hoess | Affimed NV | 63 | |
| Paula Ragan | X4 Pharmaceuticals | 54 | |
| Chris Martin | ADC Therapeutics SA | N/A | |
| James Noble | Adaptimmune Therapeutics Plc | 54 | |
| Adrian Rawcliffe | Adaptimmune Therapeutics Plc | 52 | |
| Christopher Martin | ADC Therapeutics SA | 62 | |
Management Performance
| Return On Equity | 0.0874 | ||||
| Return On Asset | 0.0355 |
Exelixis Leadership Team
Elected by the shareholders, the Exelixis' board of directors comprises two types of representatives: Exelixis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Exelixis. The board's role is to monitor Exelixis' management team and ensure that shareholders' interests are well served. Exelixis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Exelixis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Alan Garber, Independent Director | ||
| Susan Hubbard, Executive Vice President - Public Affairs and Investor Relations | ||
| Gregg Bernier, VP Marketing | ||
| George Scangos, Independent Director | ||
| Christopher Senner, CFO, Executive Vice President | ||
| Carl Feldbaum, Independent Director | ||
| Maria Freire, Director | ||
| Deborah Burke, CFO, Sr. VP and Controller | ||
| Anne MD, Senior Safety | ||
| Julie Smith, Director | ||
| Peter Lamb, Chief Scientific Officer and Executive VP of Discovery Research | ||
| Patrick Haley, Senior Vice President - Commercial | ||
| Vincent Marchesi, Independent Director | ||
| Laura Dillard, Executive Resources | ||
| Lance Willsey, Independent Director | ||
| Pamela Simonton, Executive Vice President | ||
| William MD, Senior Affairs | ||
| Michael Morrissey, CEO and President and Director | ||
| Patrick MBA, Executive Commercial | ||
| Dana Aftab, Executive Officer | ||
| Jeffrey Hessekiel, Executive Vice President General Counsel | ||
| George Poste, Independent Director | ||
| Jeffrey JD, General VP | ||
| Stelios Papadopoulos, Chairman and Member of Audit Committee | ||
| Jack Wyszomierski, Independent Director | ||
| Charles Cohen, Independent Director | ||
| MBA MBA, Ex Commercial | ||
| Gisela Schwab, Executive Vice President Chief Medical Officer |
Exelixis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Exelixis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0874 | ||||
| Return On Asset | 0.0355 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 6.15 B | ||||
| Shares Outstanding | 294.8 M | ||||
| Shares Owned By Insiders | 2.23 % | ||||
| Shares Owned By Institutions | 90.58 % | ||||
| Number Of Shares Shorted | 6.83 M | ||||
| Price To Earning | 48.17 X |
Pair Trading with Exelixis
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Exelixis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Exelixis will appreciate offsetting losses from the drop in the long position's value.Moving together with Exelixis Stock
| 0.65 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.75 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Exelixis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Exelixis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Exelixis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Exelixis to buy it.
The correlation of Exelixis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Exelixis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Exelixis moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Exelixis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Exelixis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.Note that the Exelixis information on this page should be used as a complementary analysis to other Exelixis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Complementary Tools for Exelixis Stock analysis
When running Exelixis' price analysis, check to measure Exelixis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Exelixis is operating at the current time. Most of Exelixis' value examination focuses on studying past and present price action to predict the probability of Exelixis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Exelixis' price. Additionally, you may evaluate how the addition of Exelixis to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Exelixis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exelixis. If investors know Exelixis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exelixis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 0.65 | Revenue Per Share 5.753 | Quarterly Revenue Growth 0.131 | Return On Assets 0.0355 |
The market value of Exelixis is measured differently than its book value, which is the value of Exelixis that is recorded on the company's balance sheet. Investors also form their own opinion of Exelixis' value that differs from its market value or its book value, called intrinsic value, which is Exelixis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exelixis' market value can be influenced by many factors that don't directly affect Exelixis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exelixis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Exelixis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exelixis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.